POINT logo light blue (png).png
POINT Biopharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights
13. November 2023 07:30 ET | POINT Biopharma
INDIANAPOLIS, Nov. 13, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
POINT logo light blue (png).png
POINT Biopharma and Athebio Announce Partnership to Develop Designed Ankyrin Repeat Protein Targeted Radioligands
18. September 2023 08:00 ET | POINT Biopharma
INDIANAPOLIS and SCHLIEREN-ZURICH, Switzerland, Sept. 18, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery,...
POINT logo light blue (png).png
POINT Biopharma Reports Second Quarter 2023 Financial Results and Provides Business Highlights
14. August 2023 07:30 ET | POINT Biopharma
Enrollment in PNT2002's SPLASH trial is complete and topline data is expected in the fourth quarter of 2023 Next-generation actinium-225 PSMA program PNT2001 phase 1 trial design released; first...
POINT logo light blue (png).png
ITM and POINT Biopharma Expand Global Supply Agreement for n.c.a. Lutetium-177
31. Juli 2023 09:00 ET | POINT Biopharma
GARCHING / MUNICH, Germany and INDIANAPOLIS, July 31, 2023 (GLOBE NEWSWIRE) -- ITM Isotope Technologies Munich SE (ITM), a leading radiopharmaceutical biotech company and POINT Biopharma Global Inc....
POINT logo light blue (png).png
POINT Biopharma and AdvanCell to Collaborate in the Development of Lead-212-Labeled Radioligands
26. Juni 2023 07:45 ET | POINT Biopharma
INDIANAPOLIS and SYDNEY, Australia, June 26, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and...
POINT logo light blue (png).png
POINT Biopharma Expands Its Research with Next-Generation Isotopes, Publishing New Preclinical Data at SNMMI’s Annual Congress
26. Juni 2023 07:30 ET | POINT Biopharma
Auger electron and beta emitting isotope terbium-161 was paired with POINT’s FAP-targeted PNT6555 ligand and showed robust anti-tumor efficacy, similar to actinium-225 and lutetium-177 labeled PNT6555...
POINT logo light blue (png).png
POINT Biopharma Announces Appointment of Dr. Bridget Martell to its Board of Directors
12. Juni 2023 08:00 ET | POINT Biopharma
INDIANAPOLIS, June 12, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global access to...
POINT logo light blue (png).png
POINT Biopharma to Host Virtual Investor Day on Tuesday, June 20, 2023
07. Juni 2023 07:00 ET | POINT Biopharma
Register online today at: https://hub.pointbiopharma.com/investor-day-june-2023 INDIANAPOLIS, June 07, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”),...
POINT logo light blue (png).png
POINT Biopharma Announces FRONTIER Trial-in-Progress Poster Presentation at ASCO
25. Mai 2023 08:30 ET | POINT Biopharma
PNT2004 program’s phase 1 FRONTIER trial design to be presented Abstract to be released today at 5:00 PM ET, May 25th Poster to be available starting at 9:00 AM ET, June 3rd INDIANAPOLIS, May 25,...
POINT logo light blue (png).png
POINT Biopharma Makes Strategic Investment in Commercial-Scale Alpha-Emitting Isotope Manufacturer
15. Mai 2023 07:35 ET | POINT Biopharma
INDIANAPOLIS and LANSING, Mich., May 15, 2023 (GLOBE NEWSWIRE) -- POINT Biopharma Global Inc. (NASDAQ: PNT) (the “Company” or “POINT”), a company accelerating the discovery, development, and global...